KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Operating Income (2023 - 2025)

Biocryst Pharmaceuticals' Operating Income history spans 9 years, with the latest figure at $260.4 million for Q4 2025.

  • For Q4 2025, Operating Income rose 5876.06% year-over-year to $260.4 million; the TTM value through Dec 2025 reached $341.0 million, up 13508.93%, while the annual FY2025 figure was $341.0 million, 13508.93% up from the prior year.
  • Operating Income reached $260.4 million in Q4 2025 per BCRX's latest filing, up from $29.6 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $260.4 million in Q4 2025 to a low of -$81.5 million in Q4 2023.
  • Average Operating Income over 3 years is $28.6 million, with a median of $8.8 million recorded in 2024.
  • Peak YoY movement for Operating Income: skyrocketed 94.47% in 2024, then soared 5876.06% in 2025.
  • A 3-year view of Operating Income shows it stood at -$81.5 million in 2023, then surged by 94.47% to -$4.5 million in 2024, then skyrocketed by 5876.06% to $260.4 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Operating Income are $260.4 million (Q4 2025), $29.6 million (Q3 2025), and $29.8 million (Q2 2025).